CN203970951U - Medicinal eye sticker - Google Patents
Medicinal eye sticker Download PDFInfo
- Publication number
- CN203970951U CN203970951U CN201420445449.4U CN201420445449U CN203970951U CN 203970951 U CN203970951 U CN 203970951U CN 201420445449 U CN201420445449 U CN 201420445449U CN 203970951 U CN203970951 U CN 203970951U
- Authority
- CN
- China
- Prior art keywords
- layer
- medicine
- eye sticker
- polylactic acid
- thickness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of medicinal eye sticker, comprises the medically polylactic acid rete of accreditation, medicine layer, and gelatin layer, overlay film, described polylactic acid membrane layer thickness accounts for the 1/8-1/6 of medicine layer thickness; Described medicine layer tool honeycomb structure, thickness is 50-60 μ m; Described gelatin layer thickness is 1/10 of medicine layer thickness; Described coating layer is 1/10 of medicine layer thickness; Described medicine layer is between polylactic acid rete and gelatin layer; Described coating layer is close to gelatin layer, is positioned at eye sticker outermost layer.This eye sticker is a kind of medicinal eye sticker that can adjuvant therapy of diabetes patient macular edema, solves medicine for external use in prior art and is difficult to break through blood-retina barrier, is difficult to bring into play the problem of drug effect, and simple in structure, design science is reasonable, and cost is lower.
Description
Technical field
This utility model relates to a kind of sugared net patient medical assistant product, particularly a kind of medicinal eye sticker.
Background technology
Blood-retina barrier (blood-retinal barrier, BRB) as blood-brain barrier, can stop that vessel inner blood composition, macromolecular substances and toxicant leak into retina, to maintain the transparency of optical medium, maintain best retina hydration and retinal thickness, maintain the dynamic equilibrium of retina microenvironment.Therefore, complete BRB is that to maintain the normal 26S Proteasome Structure and Function of retina necessary.BRB is divided into interior barrier (inner-blood-retinal barrier, iBRB) and external shield (outer blood-retinal barrier, oBRB).FfiRB is mainly made up of the tight connection (tight-junctions, TJs) between retinal capillary endotheliocyte.Pericyte and neurogliocyte play support effect to ffiRB.OBRB is mainly by two adjacent retinal pigment epitheliums (retinal pigment epithelium; RPE) nearly top, side plasma membrane outer plate close contact form. TJs form; being continuous net-shaped is looped around around each epithelial cell; stop that choriocapillary blood leakage is to retina, with a ffiRB-common protection retina microenvironment.Under pathological state (as hypoxic-ischemic, inflammation, blood vessel tractive or Developmental and Metabolic Disorder etc.), TJs between capillary endothelial cell and RPE is opened, barrier destroys, blood constituent and macromolecular substances leak into retinal tissue gap by lumen of vessels and RPE, form retinal edema.The edema that betides macular area is called macular edema, and macular edema is the even blind main cause of visual deterioration, and therefore the treatment of macular edema is very important.
In order to overcome blood-paropion barrier, adopt intravitreal method, but long-term intravitreal has larger intraocular toxicity more, drug effect is lasting not, because of intravitreal injection repeatedly, has also increased intraocular infection and hemorrhage risk simultaneously.In order to maintain effective drug level, research tendency is drug application slow-released system (drug delivery system both at home and abroad, DDS) medicine slowly or is controlledly discharged at eye, the dosage and the number of times that reduce dosing eyes, obviously improve the bioavailability of medicine and reduce toxicity.The DDS of application is mainly divided into implanting device and injection microgranule at present.Implanting device can be divided into: (1) non-biodegradation implanting device, (2) biodegradation implanting device: hydrophobicity and hydrophilic.Injection microgranule mainly contain: (1) liposome, (2) microsphere and nanoparticles: hydrophobicity and hydrophilic, (3) other: emulsion, micelle etc.But there is following problem in DDS at present: opaque affecting one's power of vision, and drug diffusion is inhomogeneous, and pharmaceutical dosage form is few, and its price comparison costliness, seriously limits its popularization.
Laser therapy is also a kind of effective measures that treatment sugar is netted at present at present, but due to its having relatively high expectations to operation doctor, also individual patient is had to higher requirement in addition, or accidentally also can cause new new vessels, cause the vicious cycle of patient's state of an illness, therefore this therapeutic modality also exists certain drawback.
At present, along with the fast development of modern biomaterial, by improving the architectural feature of eye mask, treating sugared net by application compress film has become a kind of possibility.
Utility model content
For the deficiencies in the prior art, this utility model provides a kind of medicinal eye sticker that can adjuvant therapy of diabetes patient macular edema, solves medicine for external use in prior art and is difficult to break through blood-retina barrier, is difficult to bring into play the problem of drug effect.This medicinal eye sticker is simple in structure, and design science is reasonable, and cost is lower.
This utility model solves its technical problem and is achieved through the following technical solutions:
A kind of medicinal eye sticker is provided, comprises the medically polylactic acid rete of accreditation, medicine layer, gelatin layer, overlay film, is characterized in that, described polylactic acid membrane layer thickness accounts for the 1/8-1/6 of medicine layer thickness; Described medicine layer tool honeycomb structure, thickness is 50-60 μ m; Described gelatin layer thickness is 1/10 of medicine layer thickness; Described coating layer is 1/10 of medicine layer thickness; Described medicine layer is between polylactic acid rete and gelatin layer; Described coating layer is close to gelatin layer, is positioned at eye sticker outermost layer.
And described polylactic acid layers membrane porosity is 40-60%.
And described honeycomb structure is regular hexagon, circle or oval.
And coating layer is adhesive, it is the smooth ground paper that processed through paraffin or methyl-silicone oil on surface.
And, composition together with described polylactic acid rete, medicine layer, gelatin layer overlays with coating layer.
Compared with prior art, this utility model polylactic acid tunic can directly be attached near the eyes on skin, and gentle non-stimulated, drug particles can see through this film and infiltrate optical fundus, part polylactic acid molecule can be combined with drug particles, the drug particles that formation has slow releasing function enters blood circulation near the eyes, to reach effect of long-acting treatment ocular disease.Medicine layer is the cellular layer of tool, can directly drug particles be sparged wherein, above covers gelatin layer, and protection medicine is not suffered a loss, and outermost layer is coating layer, and protection medicine film, avoids polluting, easy to carry and use.
Brief description of the drawings
Fig. 1 is a kind of example structure schematic diagram of the medicinal eye sticker of this utility model.
Fig. 2 be the medicinal eye sticker of this utility model medicine layer look down structural representation.
Detailed description of the invention
By reference to the accompanying drawings this utility model is further described now.The schematic diagram that these accompanying drawings are simplification only illustrates basic structure of the present utility model in a schematic way, and therefore it only shows the formation relevant with this utility model, can not be interpreted as the restriction to this utility model embodiment.
Embodiment 1
A kind of medicinal eye sticker, comprises the medically polylactic acid rete 4 of accreditation, medicine layer 3, and gelatin layer 2, overlay film 1, is characterized in that, described polylactic acid rete 4 thickness account for the 1/8-1/6 of medicine layer thickness; Described medicine layer 3 tool honeycomb structures, thickness is 50-60 μ m; Described gelatin layer 2 thickness are 1/10 of medicine layer thickness; Described coating layer 1 is 1/10 of medicine layer thickness; Described medicine layer 3 is between polylactic acid rete 4 and gelatin layer 2; Described coating layer 1 is close to gelatin layer 2, is positioned at eye sticker outermost layer.
And medicinal eye sticker polylactic acid tunic 4 porositys are 40-60%; Medicine layer 3 honeycomb structures are regular hexagon, circle or oval; Coating layer 1 is adhesive, is the smooth ground paper that processed through paraffin or methyl-silicone oil on surface.Polylactic acid rete 4, medicine layer 3, gelatin layer 2 form together with overlaying with coating layer 1.
Embodiment 2
A kind of medicinal eye sticker, comprises the medically polylactic acid rete 4 of accreditation, medicine layer 3, and gelatin layer 2, overlay film 1, is characterized in that, described polylactic acid rete 4 thickness account for 1/6 of medicine layer thickness; Described medicine layer 3 tool honeycomb structures, thickness is 55 μ m; Described gelatin layer 2 thickness are 1/10 of medicine layer thickness; Described coating layer 1 is 1/10 of medicine layer thickness; Described medicine layer 3 is between polylactic acid rete 4 and gelatin layer 2; Described coating layer 1 is close to gelatin layer 2, is positioned at eye sticker outermost layer.
And medicinal eye sticker polylactic acid tunic 4 porositys are 45%; Medicine layer 3 honeycomb structures are regular hexagon, circle or oval; Coating layer 1 is adhesive, is the smooth ground paper that processed through methyl-silicone oil on surface.Polylactic acid rete 4, medicine layer 3, gelatin layer 2 form together with overlaying with coating layer 1.
Drug particles or the gel solution for the treatment of ocular disease can be sprayed into embodiment 1 and the cellular medicine layer of embodiment 2; then by polylactic acid rete 4, medicine layer 3, gelatin layer 2; overlay film 1 overlays together; make definite shape, stick near the eyes, this kind of structure plaster is easy to carry and use; non-stimulated to skin around the eyes; can directly arrive focus, the medicament slow release granule of formation is easily broken through blood-retina barrier, is a kind of medical assistance articles for use of good treatment macular edema.
Claims (5)
1. a medicinal eye sticker, comprises the medically polylactic acid rete of accreditation, medicine layer, and gelatin layer, overlay film, is characterized in that, described polylactic acid membrane layer thickness accounts for the 1/8-1/6 of medicine layer thickness; Described medicine layer tool honeycomb structure, thickness is 50-60 μ m; Described gelatin layer thickness is 1/10 of medicine layer thickness; Described coating layer is 1/10 of medicine layer thickness; Described medicine layer is between polylactic acid rete and gelatin layer; Described coating layer is close to gelatin layer, is positioned at eye sticker outermost layer.
2. medicinal eye sticker according to claim 1, is characterized in that, described polylactic acid layers membrane porosity is 40-60%.
3. medicinal eye sticker according to claim 1, is characterized in that, described honeycomb structure is regular hexagon, circle or oval.
4. medicinal eye sticker according to claim 1, is characterized in that, described coating layer is adhesive, is the smooth ground paper that processed through paraffin or methyl-silicone oil on surface.
5. medicinal eye sticker according to claim 1, is characterized in that, composition together with described polylactic acid rete, medicine layer, gelatin layer overlays with coating layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420445449.4U CN203970951U (en) | 2014-08-07 | 2014-08-07 | Medicinal eye sticker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420445449.4U CN203970951U (en) | 2014-08-07 | 2014-08-07 | Medicinal eye sticker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203970951U true CN203970951U (en) | 2014-12-03 |
Family
ID=51968423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201420445449.4U Expired - Fee Related CN203970951U (en) | 2014-08-07 | 2014-08-07 | Medicinal eye sticker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203970951U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105326816A (en) * | 2014-08-07 | 2016-02-17 | 天津法莫西医药科技有限公司 | Eye patch for medical use |
-
2014
- 2014-08-07 CN CN201420445449.4U patent/CN203970951U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105326816A (en) * | 2014-08-07 | 2016-02-17 | 天津法莫西医药科技有限公司 | Eye patch for medical use |
| CN105326816B (en) * | 2014-08-07 | 2019-04-09 | 舒泰神（北京）生物制药股份有限公司 | Medicinal eye sticker |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi et al. | A rapid corneal healing microneedle for efficient ocular drug delivery | |
| Kaji et al. | Drug delivery devices for retinal diseases | |
| US10617559B2 (en) | High-precision drug delivery by dual-domain ocular device | |
| Mandal et al. | Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders. | |
| Li et al. | Nature-derived bionanomaterials for sustained release of 5-fluorouracil to inhibit subconjunctival fibrosis | |
| Juliana et al. | Promising approach in the treatment of glaucoma using nanotechnology and nanomedicine-based systems | |
| Li et al. | Smart and versatile biomaterials for cutaneous wound healing | |
| EP3536352A1 (en) | Keratoconjunctival cover sheet and method for producing keratoconjunctival cover sheet | |
| Meng et al. | Novel double-layer dissolving microneedles for transmucosal sequential delivery of multiple drugs in the treatment of oral mucosa diseases | |
| CN107049938A (en) | A kind of eye drops for being used to treat dry eyes | |
| CN109862899A (en) | The composition and method for treating dry eye syndrome and other traumatic noncornified epithelium surfaces | |
| CN106890352A (en) | A kind of bioactive functions dressing for treating diabetes | |
| CN203970951U (en) | Medicinal eye sticker | |
| CN102961324B (en) | Gel for lysozyme eye and preparation method thereof | |
| Wadhwa et al. | Bimatoprost: Promising novel drug delivery systems in treatment of glaucoma | |
| CN102166205B (en) | The medical usage of paeonol and derivant thereof | |
| CN105326816A (en) | Eye patch for medical use | |
| CN107929810B (en) | Layer-by-layer self-assembled film and preparation method and application thereof | |
| CN105214071A (en) | A kind of size variance eye drop and preparation method thereof | |
| CN103006706A (en) | Amniotic membrane liposome for ocular surface reconstruction and preparation method and application thereof | |
| CN204766452U (en) | Eyes massage appearance of massage bridge of nose | |
| CN102526112B (en) | Sustained-release pearl clear-sighted eye drops and preparation method thereof | |
| Wilson | Ophthalmic Formulation | |
| CN103405609A (en) | Traditional Chinese medicine preparation for treating cataract | |
| CN108186669A (en) | Application of the chitosan as treatment traumatic optic neuropathy drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141203 Termination date: 20160807 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |